NewAmsterdam Pharma Company N.V. (NAMS)Healthcare | Biotechnology | Naarden, Netherlands | NasdaqGM
25.90 USD
-0.89
(-3.322%) ⇩
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 25.90 |
Hot Take ↕ | Aug. 22, 2026, 4:54 a.m. EDT
The fundamental reality here is stark: NewAmsterdam Pharma is a speculative biotech play with no current revenue, negative earnings, and a massive cash burn that has already eroded nearly 80% of its reported sales year-over-year. While the balance sheet remains technically healthy due to minimal debt, the business is currently losing money rapidly. The stock's recent price action shows a struggle to maintain gains, trading well below its 200-day average despite a long-term chart that looks impressive only because of the massive base from several years ago. The disconnect between the 'Strong Buy' analyst consensus and the deteriorating financials suggests analysts are pricing in a future catalyst that hasn't materialized yet. Options activity confirms this tension; traders are buying deep puts to protect against failure while hoping for a moonshot rally on a clinical win. For a standard investor, the lack of dividends, negative free cash flow, and reliance on a single potential future event make this a high-risk, non-income vehicle where the odds of capital preservation are currently lower than the odds of a successful clinical outcome. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.071824 |
| MSTL | 0.071830 |
| AutoETS | 0.071865 |
| AutoARIMA | 0.085671 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 37% |
| H-stat | 5.47 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.491 |
| Excess Kurtosis | -0.80 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 0.013 |
| Revenue per Share | 0.059 |
| Market Cap | 3,096,012,544 |
| Forward P/E | -16.50 |
| Beta | 0.11 |
| Previous Name | Frazier Lifesciences Acquisition Corporation |
| Website | https://www.newamsterdampharma.com |
As of Aug. 22, 2026, 4:54 a.m. EDT: Speculators are positioning aggressively for volatility rather than a specific directional breakout. In the near term (Sept-Dec 2026), there is heavy volume in out-of-the-money calls (especially the $35 strike) suggesting a hope for a rally, but this is immediately countered by massive open interest in deep out-of-the-money puts ($20-$25 strikes) expiring later in 2027. This 'long gamma' structure indicates traders are betting on a binary event—likely a clinical trial result—that could swing the stock significantly in either direction, rather than a steady grind higher.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.051563144 |
| Address1 | Gooimeer 2-35 |
| All Time High | 42.205 |
| All Time Low | 5.633 |
| Ask | 33.17 |
| Ask Size | 2 |
| Average Daily Volume10 Day | 964,790 |
| Average Daily Volume3 Month | 1,123,398 |
| Average Volume | 1,123,398 |
| Average Volume10Days | 964,790 |
| Beta | 0.11 |
| Bid | 19.66 |
| Bid Size | 2 |
| Book Value | 5.367 |
| City | Naarden |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | Netherlands |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 25.9 |
| Current Ratio | 9.033 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 26.875 |
| Day Low | 25.53 |
| Debt To Equity | 0.013 |
| Display Name | NewAmsterdam Pharma Company |
| Earnings Timestamp | 1,785,933,000 |
| Earnings Timestamp End | 1,793,795,400 |
| Earnings Timestamp Start | 1,793,795,400 |
| Ebitda | -244,163,008 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -10.084 |
| Enterprise To Revenue | 345.772 |
| Enterprise Value | 2,462,240,768 |
| Eps Current Year | -1.65517 |
| Eps Forward | -1.5700487 |
| Eps Trailing Twelve Months | -2.09 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 30.2326 |
| Fifty Day Average Change | -4.3325996 |
| Fifty Day Average Change Percent | -0.14330886 |
| Fifty Two Week Change Percent | 5.1563144 |
| Fifty Two Week High | 42.205 |
| Fifty Two Week High Change | -16.305002 |
| Fifty Two Week High Change Percent | -0.38632867 |
| Fifty Two Week Low | 23.05 |
| Fifty Two Week Low Change | 2.8500004 |
| Fifty Two Week Low Change Percent | 0.12364427 |
| Fifty Two Week Range | 23.05 - 42.205 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,612,881,000,000 |
| Float Shares | 82,897,831 |
| Forward Eps | -1.5700487 |
| Forward P E | -16.496304 |
| Free Cashflow | -45,358,376 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 100 |
| Fullday Change | -0.890001 |
| Fullday Change Percent | -3.32214 |
| Fullday Price | 25.9 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 1.0 |
| Gross Profits | 7,121,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.00894 |
| Held Percent Institutions | 1.0567299 |
| Implied Shares Outstanding | 119,537,169 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,022-11-23 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands. |
| Long Name | NewAmsterdam Pharma Company N.V. |
| Market | us_market |
| Market Cap | 3,096,012,544 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_685404834 |
| Most Recent Quarter | 1,782,777,600 |
| Name Change Date | 2,026-08-29 |
| Net Income To Common | -259,504,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 3,202,400,757 |
| Number Of Analyst Opinions | 15 |
| Open | 26.66 |
| Operating Cashflow | -143,462,000 |
| Operating Margins | -17.52607 |
| Payout Ratio | 0.0 |
| Phone | 31 35 206 2971 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 25.9 |
| Post Market Time | 1,787,959,806 |
| Prev Name | Frazier Lifesciences Acquisition Corporation |
| Previous Close | 26.79 |
| Price Eps Current Year | -15.64794 |
| Price Hint | 2 |
| Price To Book | 4.825787 |
| Price To Sales Trailing12 Months | 434.77216 |
| Profit Margins | 0.0 |
| Quick Ratio | 8.759 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.890001 |
| Regular Market Change Percent | -3.32214 |
| Regular Market Day High | 26.875 |
| Regular Market Day Low | 25.53 |
| Regular Market Day Range | 25.53 - 26.875 |
| Regular Market Open | 26.66 |
| Regular Market Previous Close | 26.79 |
| Regular Market Price | 25.9 |
| Regular Market Time | 1,787,947,200 |
| Regular Market Volume | 1,035,970 |
| Return On Assets | -0.20105 |
| Return On Equity | -0.36811 |
| Revenue Growth | -0.807 |
| Revenue Per Share | 0.059 |
| Sand P52 Week Change | 0.20204377 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 119,537,169 |
| Shares Percent Shares Out | 0.105900005 |
| Shares Short | 12,654,106 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 9,176,420 |
| Short Name | NewAmsterdam Pharma Company N.V |
| Short Percent Of Float | 0.123900004 |
| Short Ratio | 11.19 |
| Source Interval | 15 |
| Symbol | NAMS |
| Target High Price | 60.21553 |
| Target Low Price | 38.136734 |
| Target Mean Price | 51.543076 |
| Target Median Price | 52.18656 |
| Total Cash | 633,854,016 |
| Total Cash Per Share | 5.303 |
| Total Debt | 82,000 |
| Total Revenue | 7,121,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -2.09 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 32.882324 |
| Two Hundred Day Average Change | -6.9823246 |
| Two Hundred Day Average Change Percent | -0.2123428 |
| Type Disp | Equity |
| Volume | 1,035,970 |
| Website | https://www.newamsterdampharma.com |
| Zip | 1,411 DC |